Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 52

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 52
---
.8 million change in accrued expenses and other current liabilities.

30

These were offset by:

•$36.3 million of non-cash amounts included in net loss, which primarily consisted of stock-based compensation expense, restricted stock issuance expense, non-cash lease expense, depreciation expense, and change in fair value of short-term investment — related party;

•$1.9 million change in prepaid and other current assets; and

•$1.6 million change in accounts payable.

Net cash used in operating activities for the nine months ended September 30, 2024 was driven primarily by the following uses of cash:

•$153.6 million net loss;

•$55.0 million change in collaboration receivable — related party;

•$13.5 million change in accrued settlement payment — related party;

•$9.5 million change in prepaid and other current assets;

•$7.7 million change in accounts payable; and

•$6.0 million change in lease liabilities.

These were offset by:

•$32.3 million of non-cash amounts included in net loss, which primarily consisted of stock-based compensation expense, non-cash lease expense, depreciation and amortization expense, and change in fair value of short-term investment — related party;

•$71.9 million change in deferred revenue from consideration received from BMS in September 2024; and

•$2.0 million change in accrued expenses and other current liabilities.

Investing Activities 

Net cash used in investing activities for the nine months ended September 30, 2025 was driven primarily by the following:

•$132.9 million of purchases of marketable securities, net of maturities; and

•$4.2 million of purchases of property and equipment.

Net cash provided by investing activities for the nine months ended September 30, 2024 was driven primarily by $25.0 million of maturities of marketable securities, net of purchases, offset by $5.5 million of purchases of property and equipment.

Financing Activities 

Net cash provided by financing activities for the nine months ended September 30, 2025 was driven primarily by the following:

•$138.4 million of net proceeds from issuances of common stock in our August 2025 public offering; and

•$12.0 million of proceeds received under our agreement with Cystic Fibrosis Foundation.

31

Net cash provided